AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

NanoVibronix, Inc. Common Stock

$3.43 -$25.97 (-88.33%)
NASDAQ · 14 Sep 2026 19:59 UTC
Previous Close
$3.58
Day Range
$3.33$3.58
Year Range
$0.29$5.98
Market Cap
2.66M
AVG Volume
93.19K
Trailing/Forward PE
-0/-
PEG ratio
0
Dividend Yield
-
Next Earnings Date
2026-11-17
Primary Exchange
NASDAQUS
Revenue (USD)
01M2M3M2018201920202021202320242025
FEED Revenue (USD) by year
PeriodRevenue (USD)
20252.55M
20242.56M
20232.28M
20211.7M
2020623K
2019530K
2018317K
Net Income (USD)
-15M-10M-5M02018201920202021202320242025
FEED Net Income (USD) by year
PeriodNet Income (USD)
2025-14.9M
2024-3.71M
2023-3.71M
2021-14.28M
2020-4.32M
2019-5.79M
2018-4.15M
Operating Income (USD)
-15M-10M-5M02018201920202021202320242025
FEED Operating Income (USD) by year
PeriodOperating Income (USD)
2025-11.73M
2024-3.58M
2023-3.43M
2021-5.68M
2020-4.72M
2019-5.15M
2018-4.3M
EBITDA (USD)
-15M-10M-5M02018201920202021202320242025
FEED EBITDA (USD) by year
PeriodEBITDA (USD)
2025-11.46M
2024-3.67M
2023-3.48M
2021-14.22M
2020-4.16M
2019-5.73M
2018-4.27M
Cash Flows (USD)
-10M-7.5M-5M-2.5M02018201920202021202320242025
FEED Cash Flows (USD) by year
PeriodCash Flows (USD)
2025-9.43M
2024-1.97M
2023-1.88M
2021-4.37M
2020-2.5M
2019-3.87M
2018-2.69M
EPS (USD)
-2000-1500-1000-50002018201920202021202320242025
FEED EPS (USD) by year
PeriodEPS (USD)
2025-802.56
2024-137.2
2023-234.29
2021-1223.84
2020-1040.86
2019-1780.3
2018-1417.65
Expenses (USD)
05M10M15MR&DSG&ACapex2018201920202021202320242025
FEED Expenses (USD) by year
PeriodExpenses (USD)
202511.95M
20245.09M
20234.97M
20216.46M
20204.93M
20195.43M
20184.47M
Cash & Debt (USD)
02M4M6M8MCashShort Term Debt2018201920202021202320242025
FEED Cash & Debt (USD) by year
PeriodCash & Debt (USD)
20254.22M
2024752K
20233.28M
20217.74M
20207.53M
20191.34M
2018896K
Debt ratios
00.10.20.32021202320242025
FEED Debt ratios by year
PeriodDebt ratios
20250.09
20240.02
20230.12
20210.27
Margins
0%20%40%60%80%2018201920202021202320242025
FEED Margins by year
PeriodMargins
20255.99%
202458.95%
202367.32%
202145.43%
202034.35%
201953.02%
201850.16%
Return on Capital
-1000%-750%-500%-250%0%2018201920202021202320242025
FEED Return on Capital by year
PeriodReturn on Capital
2025-44.49%
2024-590.91%
2023-93.05%
2021-226.23%
2020-180.66%
2019-429.82%
2018-897.19%
Shares Outstanding
020K40K60K80K2018201920202021202320242025
FEED Shares Outstanding by year
PeriodShares Outstanding
202571.54K
202431.73K
202318.6K
202112.73K
202010.43K
20194.24K
20182.95K
Book Value Per Share (USD)
02004006002018201920202021202320242025
FEED Book Value Per Share (USD) by year
PeriodBook Value Per Share (USD)
2025468.25
202419.76
2023214.39
2021496.07
2020229.6
2019318
2018157.06
Total Assets (USD)
020M40M60M2018201920202021202320242025
FEED Total Assets (USD) by year
PeriodTotal Assets (USD)
202541.12M
20243.63M
20236.67M
20218.62M
20208.23M
20192.04M
20181.58M
Free Cash Flow Yield
-1500000%-1000000%-500000%0%med -1087.87%Mar 26May 26Jun 26Jul 26Aug 26Sep 26
FEED Free Cash Flow Yield by year
PeriodFree Cash Flow Yield
Sep 26-683.23%
Sep 26-639.33%
Sep 26-567.94%
Aug 26-1096923%
Aug 26-965947.12%
Aug 26-864559.54%
Aug 26-943810.83%
Jul 26-1195327.7%
Jul 26-989146.72%
Jul 26-907874.14%
Jul 26-714557.09%
Jul 26-726008.33%
Jun 26-655613.89%
Jun 26-562070.96%
Jun 26-455305.73%
Jun 26-434352.06%
May 26-1218.57%
May 26-1087.87%
May 26-998.86%
May 26-923.32%
May 26-923.32%
Apr 26-819.96%
Apr 26-695.41%
Apr 26-661.9%
Apr 26-560.59%
Mar 26-452.16%
Mar 26-915.62%
Mar 26-607.04%
Mar 26-546.64%
Price to Sales
00.511.5med 0.4Nov 25Jan 26Mar 26Apr 26Jun 26Jul 26Sep 26
FEED Price to Sales by year
PeriodPrice to Sales
Sep 260.89
Sep 260.95
Sep 261.07
Aug 260
Aug 260
Aug 260
Aug 260
Jul 260
Jul 260
Jul 260
Jul 260
Jul 260
Jun 260
Jun 260
Jun 260
Jun 260
May 260.3
May 260.34
May 260.37
May 260.4
May 260.4
Apr 260.45
Apr 260.53
Apr 260.56
Apr 260.66
Mar 260.82
Mar 260.4
Mar 260.61
Mar 260.68
Feb 260.67
Feb 260.88
Feb 260.9
Feb 260.93
Jan 261.03
Jan 260.35
Jan 260.42
Jan 260.74
Jan 260.78
Dec 250.82
Dec 250.96
Dec 251.31
Dec 251.33
Nov 250.09
Nov 250.08
Nov 250.09
Price to Book
00.030.050.080.1med 0.03Nov 25Jan 26Mar 26Apr 26Jun 26Jul 26Sep 26
FEED Price to Book by year
PeriodPrice to Book
Sep 260.06
Sep 260.06
Sep 260.07
Aug 260
Aug 260
Aug 260
Aug 260
Jul 260
Jul 260
Jul 260
Jul 260
Jul 260
Jun 260
Jun 260
Jun 260
Jun 260
May 260.02
May 260.03
May 260.03
May 260.03
May 260.03
Apr 260.03
Apr 260.04
Apr 260.04
Apr 260.05
Mar 260.06
Mar 260.03
Mar 260.05
Mar 260.05
Feb 260.04
Feb 260.06
Feb 260.06
Feb 260.06
Jan 260.07
Jan 260.02
Jan 260.03
Jan 260.05
Jan 260.05
Dec 250.05
Dec 250.06
Dec 250.08
Dec 250.08
Nov 250
Nov 250
Nov 250.01
NanoVibronix, Inc. Common Stock
FEED
Stockpicker

Video analysis: FEED

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: FEED

ENvue Medical Resumes U.S. Commercial Shipments of NanoVibronix PainShield® and Begins Fulfilling Open Distributor Orders

globenewswire.com · 9 Sep 2026

ENvue Medical Resumes U.S. Commercial Shipments of NanoVibronix PainShield® and Begins Fulfilling Open Distributor Orders

TYLER, Texas, Sept. 09, 2026 (GLOBE NEWSWIRE) -- ENvue Medical , Inc. (NASDAQ: FEED) (“ENvue” or the “Company”), a commercial-stage medical device company focused on real-time guided bedside feeding tube placement and therapeutic technologies, today announced that it has resumed commercial shipments of PainShield®, manufactured in the United States, and has begun fulfilling open orders from Ultra Pain Products, Inc. (“UPPI”), the Company's exclusive U.S. distribution partner for the product.

ENvue Medical Selected to Exhibit ENvue™ Navigation Platform at Vizient Innovative Technology Exchange

globenewswire.com · 2 Sep 2026

ENvue Medical Selected to Exhibit ENvue™ Navigation Platform at Vizient Innovative Technology Exchange

TYLER, Texas, Sept. 02, 2026 (GLOBE NEWSWIRE) -- ENvue Medical (NASDAQ: FEED) (“ENvue” or the “Company”), a commercial-stage medical device company focused on real-time guided bedside feeding tube placement, today announced it has been selected to exhibit its ENvue™ Navigation Platform, a minimally invasive electromagnetic navigation system guiding feeding tube placement, at the Vizient® Innovative Technology Exchange.

ENvue Medical Announces Exclusive UroShield® Distribution Agreement with Minimum Purchase Commitments of Approximately $2.6 Million

globenewswire.com · 18 Aug 2026

ENvue Medical Announces Exclusive UroShield® Distribution Agreement with Minimum Purchase Commitments of Approximately $2.6 Million

Multi-year agreement with Peak Medical expands UroShield commercialization across the United Kingdom and Republic of Ireland Multi-year agreement with Peak Medical expands UroShield commercialization across the United Kingdom and Republic of Ireland

ENvue Medical Secures Equity Financing Facility of Up to $50 Million to Support Commercial Growth, Technology Expansion and Strategic Acquisitions

globenewswire.com · 12 Aug 2026

ENvue Medical Secures Equity Financing Facility of Up to $50 Million to Support Commercial Growth, Technology Expansion and Strategic Acquisitions

TYLER, Texas, Aug. 12, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ: FEED) ("ENvue" or the "Company"), a commercial-stage medical technology company, today announced that it has entered into a securities purchase agreement (“ELOC”) with an institutional investor providing the Company with an equity facility for up to $50 million in capital (the “Facility”), subject to the terms and conditions of the agreement, including the receipt of stockholder approval.

ENvue Medical Moves NanoVibronix Manufacturing to the United States, Consolidates R&D in Tel Aviv, Israel, Increasing Operational Efficiencies and Cost Reduction Opportunities

globenewswire.com · 4 Aug 2026

ENvue Medical Moves NanoVibronix Manufacturing to the United States, Consolidates R&D in Tel Aviv, Israel, Increasing Operational Efficiencies and Cost Reduction Opportunities

TYLER, Texas, Aug. 04, 2026 (GLOBE NEWSWIRE) -- ENvue Medical , Inc. (NASDAQ: FEED) (“ENvue” or the “Company”), a commercial-stage medical device company, today announced it has completed the transition of its NanoVibronix manufacturing operations from Israel to the United States, and consolidated its research and development operations in Tel Aviv, Israel, supporting the Company's broader initiative to reduce operating expenses and improve its cost structure. “Completing the transition of our NanoVibronix product line manufacturing to the United States marks the achievement of a major strategic operational initiative for the Company,” said Doron Besser, MD, CEO of ENvue Medical.

ENvue Medical Deploys Additional Navigation Platform with Existing Customer, A Leading North Texas Medical Center

globenewswire.com · 23 Jul 2026

ENvue Medical Deploys Additional Navigation Platform with Existing Customer, A Leading North Texas Medical Center

Additional Platform Deployment at Major Academic Medical Center Reflects Increasing Commercial Demand for Bedside Feeding Tube Navigation Additional Platform Deployment at Major Academic Medical Center Reflects Increasing Commercial Demand for Bedside Feeding Tube Navigation

ENvue Medical Appoints Chairman of the Board and New Directors, Bringing Clinical, AI Governance and Capital Markets Expertise to Navigation Platform

globenewswire.com · 15 Jul 2026

ENvue Medical Appoints Chairman of the Board and New Directors, Bringing Clinical, AI Governance and Capital Markets Expertise to Navigation Platform

Zeev Rotstein, M.D. Named Chairman Following Four Decades in Health System Leadership, Including 12 Years as Director General of Sheba Medical Center Zvi Joseph and Lior Buchman Join Board, Bringing Amdocs AI Governance Leadership and $320 Million in Executed Financings and M&A, Respectively TYLER, Texas, July 15, 2026 (GLOBE NEWSWIRE) -- ENvue Medical (NASDAQ: FEED) (“ENvue,” “ENvue Medical” or the “Company”), a commercial-stage medical device company focused on real-time guided bedside feeding tube placement, today announced that Zeev Rotstein, M.D.

Envue Medical Expands AI Navigation Platform With Robotic Prototype

benzinga.com · 9 Jul 2026

Envue Medical Expands AI Navigation Platform With Robotic Prototype

ENvue Medical, Inc. (NASDAQ:FEED) announced Thursday the development and demonstration of the prototype of ENvue Drive.

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.